Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Subcutaneous Infusion of Pramlintide and Insulin in T1DM
NCT00291772Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pramlintide in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Area under the curve for glucose at 4 hours. Started Jan 2006; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00291772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291772.